drugset / Trial / NCT03386487
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
Phase 2
Completed
228 enrolled
Yale University
Columbia University · collabJohns Hopkins University · collabMedical University of South Carolina · collabNational Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)
Timeline
- Start
- 2019-01-14
- Primary completion
- 2022-07-25
- Completion
- 2022-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | REDAFAMDASTAT | Small molecule | 4 mg | Oral |